275 related articles for article (PubMed ID: 30205127)
1. Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2.
Xiang Y; Shan W; Huang Y
Int J Pharm; 2018 Nov; 551(1-2):14-22. PubMed ID: 30205127
[TBL] [Abstract][Full Text] [Related]
2. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy.
Xiang Y; Chen L; Zhou R; Huang Y
Int J Pharm; 2019 Oct; 570():118668. PubMed ID: 31494237
[TBL] [Abstract][Full Text] [Related]
3. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
4. Mitochondria-targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of α-tocopheryl succinate.
Liu Y; Li Q; Xiong X; Huang Y; Zhou Z
J Mater Chem B; 2018 Dec; 6(46):7674-7683. PubMed ID: 32254889
[TBL] [Abstract][Full Text] [Related]
5. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
7. Complexation of cell-penetrating peptide-polymer conjugates with polyanions controls cells uptake of HPMA copolymers and anti-tumor activity.
Shamay Y; Shpirt L; Ashkenasy G; David A
Pharm Res; 2014 Mar; 31(3):768-79. PubMed ID: 24019024
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
9. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
Shamay Y; Golan M; Tyomkin D; David A
J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
[TBL] [Abstract][Full Text] [Related]
10. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
11. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
12. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
14. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
15. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
16. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
17. A novel α
Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
19. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells.
Greco F; Vicent MJ; Gee S; Jones AT; Gee J; Nicholson RI; Duncan R
J Control Release; 2007 Jan; 117(1):28-39. PubMed ID: 17129632
[TBL] [Abstract][Full Text] [Related]
20. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility.
Ríhová B; Srogl J; Jelínková M; Hovorka O; Buresová M; Subr V; Ulbrich K
Ann N Y Acad Sci; 1997 Dec; 831():57-71. PubMed ID: 9616702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]